PROCESS FOR PREPARING PRAMIPEXOLE DIHYDROCHLORIDE TABLETS

• US 20080254118A1
• Filed: 04/11/2007
• Published: 10/16/2008
• Est. Priority Date: 04/11/2007
• Status: Abandoned Application

• Current Assignee: Boehringer Ingelheim International GmbH (C.H. Boehringer Sohn AG & Co. KG), Boehringer Ingelheim Pharma GmbH & Company Kg (C.H. Boehringer Sohn AG & Co. KG)
• Original Assignee: Boehringer Ingelheim Pharma GmbH & Company Kg (C.H. Boehringer Sohn AG & Co. KG)
• Inventors: Wernersbach, Hans-Werner
• Application Number:
  US11/734,041
• Publication Number:
  US 20080254118A1
• Time in Patent Office: Days
• US Class Current: 424/464
• CPC Class Codes: A61K 31/428 condensed with carbocyclic rings
• CPC Class Codes: A61K 9/1623 Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
• CPC Class Codes: A61P 25/16 Anti-Parkinson drugs

Abstract

The present invention relates to a process for preparing tablets of pramipexole dihydrochloride. In particular, the present invention relates to a process for preparing tablets of pramipexole dihydrochloride wherein the tablets exhibit enhanced storage stability properties.

Claims

1. A process for preparing pramipexole dihydrochloride tablets comprising intra-granular tableting ingredients, pramipexole dihydro chloride or a pharmaceutically acceptable solvate thereof, a binder and extra-granular tableting agents, wherein the process is performed in a closed system and comprises the steps of:

(a) loading particles of the intra-granular tableting ingredients into a fluid bed granulator,

(b) dissolving the pramipexole dihydrochloride or pharmaceutically acceptable solvate thereof in water and povidone to form an aqueous pramipexole dihydrochloride solution and spraying the pramipexole dihydrochloride solution to the particles of intra-granular tableting ingredients in the fluid bed granulator,

(c) preparing a binder solution and adding the binder solution to the fluid bed granulator,

(d) mixing the particles of intra-granular tableting ingredients, pramipexole dihydrochloride solution and binder solution in the fluid bed granulator to form a premix,

(e) granulating said premix to form a granulated premix,

(f) drying said granulated premix to an endpoint moisture content of from about 1.0% to about 2.5%,

(g) mixing said granulated premix of step (f) with the extra-granular tableting agents and blending to form a final blend,

(h) compressing the final blend into tablets using a tablet press.

2. The process of claim 1 further comprising the step of sizing the intra-granular tableting agents prior to loading to a substantially uniform size.

3. The process of claim 1 wherein pramipexole dihydrochloride monohydrate solvate is used.

4. The process of claim 1 wherein the binder solution is an aqueous suspension comprising corn starch.

5. The process of claim 1 wherein the intra-granular tableting ingredients comprise mannitol-D, colloidal silicone dioxide, and corn starch.

6. The process of claim 1 wherein the extra-granular tableting agents comprise colloidal silicon dioxide, starch and magnesium stearate.

7. The process of claim 5 wherein the mannitol-D has no more than 10% beta modification product present.

8. A product produced in accordance with the process of claim 1.

9. A pharmaceutical tablet formulation comprising pramipexole dihydrochloride or a pharmaceutically acceptable solvate thereof, wherein the average amount of pramipexole dihydrochloride or pharmaceutically acceptable solvate thereof remaining in the tablet at 18 months under storage conditions of 25°

C. and a relative humidity of 60% is at least about 97% of the labeled amount.

10. The tablet formulation of claim 9 wherein the pramipexole dihydrochloride is pramipexole dihydrochloride monohydrate solvate.

11. A pharmaceutical tablet formulation comprising pramipexole dihydrochloride, wherein the average amount of pramipexole dihydrochloride remaining in the tablet at 24 months under storage conditions of 25°

C. and a relative humidity of 60% is at least about 95% of the labeled amount.

12. The tablet formulation of claim 11 wherein the pramipexole dihydrochloride is pramipexole dihydrochloride monohydrate solvate.

13. The pharmaceutical tablet of claim 11 wherein the average amount of pramipexole dihydrochloride is at least about 97% of the labeled amount.

14. A pharmaceutical tablet formulation comprising pramipexole dihydrochloride or a pharmaceutically acceptable solvate thereof, wherein the average amount of total degradation product present in the tablet at 18 months under storage conditions of 25°

C. and a relative humidity of 60% is less than about 1.0%.